Mr. Michael Frank reports

REVIVE THERAPEUTICS TO PURSUE THE PSYCHEDELIC MARKET WITH AGREEMENT AND INVESTMENT IN RED LIGHT HOLLAND FINANCING

Revive Therapeutics Ltd. has entered into a supply and collaboration agreement with Red Light Holland Financing Inc., an arm's-length party.

Pursuant to the agreement Red Light will sell to Revive a consistent strain of truffles for the sole purpose of Revive undertaking research and development on the suitability and implementation of its novel cannabinoid delivery technology with respect to the truffles and their extracts. Red Light has also agreed to, upon request, provide Revive with any information, studies, papers and other information it may have pertaining to the truffles which may be deemed to be beneficial to Revive for undertaking the research and development.

"Revive is excited to be working with Red Light to explore the use of its delivery technology with unique products such as truffles," stated Michael Frank, the president of Revive. "We are confident that the results of Revive's research will highlight the versatility of its cannabinoid delivery platform."

"As Red Light Holland heads down the road of securing its facility in the Netherlands and commencing our cultivation of premium Red Light truffles, we are elated to be partnering and eventually aiming to supply companies with our truffles, such as Revive, who will perform true clinical testing in hopes of publishing groundbreaking and progressive medical results," said Todd Shapiro, chief executive officer of Red Light Holland.

In addition, as a condition of the agreement, Revive has agreed to subscribe for 2.5 million subscription receipts of Red Light at a price of six cents per subscription receipt for an aggregate consideration of $150,000. Each subscription receipt shall entitle Revive, upon conversion and with any additional consideration, to acquire one common share in the capital of Red Light. In consideration for the subscription receipts, Revive will issue to Red Light an aggregate of three million common shares in the capital of Revive at a price of five cents per share for aggregate consideration of $150,000.

About Revive Therapeutics Ltd.

Revive is a cannabis life sciences company focused on the research, development and commercialization of novel cannabinoid-based products. Revive's novel cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation and wound care. Revive's cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases.